The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 3, 1996, Pages 295-307

  Capon, Deborah A ^a   Bochner, Felix ^a   Kerry, Nicole ^a   Mikus, Gerd ^a,b   Danz, Catherine ^a   Somogyi, Andrew A ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHOXYMORPHINAN; CAPSAICIN; DEXTROMETHORPHAN; DEXTRORPHAN; DRUG METABOLITE; NORLEVORPHANOL; PLACEBO; QUINIDINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; COUGHING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL;

ADULT; AEROSOLS; ANTI-ARRHYTHMIA AGENTS; ANTITUSSIVE AGENTS; AREA UNDER CURVE; CAPSAICIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COUGH; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; FEMALE; HUMANS; MALE; MATCHED-PAIR ANALYSIS; POLYMORPHISM, GENETIC; QUINIDINE; REFERENCE VALUES;

EID: 0029853347     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90056-9     Document Type: Article

References (63)

1. Cass LJ, Frederik WS. Evaluation of a new antitussive agent. N Engl J Med 1953;249:132-6.
2. Cass LJ, Frederik WS, Andosca JB. Quantitative comparison of dextromethorphan hydrobromide and codeine. Am J Med Sci 1954;227:291-6.
3. Ralph N. Evaluation of a new cough suppressant. Am J Med Sci 1954;227:297-303.
4. Matthys H, Bleicher B, Bleicher U. Dextromethorphan and codeine: objective assessment of antitussive activity in patients with chronic cough. J Int Med Res 1983;11:92-100.
5. Aylward M, Maddock J, Davies D, Protheroe D, Leideman T. Dextromethorphan and codeine: comparison of plasma kinetics and antitussive effects. Eur J Resp Dis 1984;65:283-91.
6. Barnhart JW. The urinary excretion of dextromethorphan and three metabolites in dogs and humans. Toxicol Appl Pharmacol 1980;55:43-8.
7. Pfaff G, Briegel P, Lamprecht I. Inter-individual variation in the metabolism of dextromethorphan. Int J Pharm 1983;14:173-89.
8. Schmid B, Bircher J, Preisig R, Kupfer A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985;38:618-24.
9. Küpfer A, Schmid B, Pfaff G. Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica 1986;16:421-33.
10. Larrey D, Amouyal G, Tinel M, Letteron P, Berson A, Labbe G, et al. Polymorphism of dextromethorphan oxidation in a French population. Br J Clin Pharmacol 1987;24:676-9.
11. Henthorn TK, Benitez J, Avram MJ, Martinez C, LLerena A, Cobaleda J, et al. Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis. Clin Pharmacol Ther 1989;45:328-33.
12. Kerry NL, Somogyi AA, Bochner F, Mikus G. The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. Br J Clin Pharmacol 1994;38:243-8.
13. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharmacol Ther 1990;46:377-94.
14. Meyer UA, Skoda RC, Zanger UM. The genetic polymorphism of debrisoquine/sparteine metabolism - molecular mechanisms. Pharmacol Ther 1990;46:297-308.
15. Gonzalez FJ, Meyer UA. Molecular genetics of the debrisoquine-sparteine polymorphism. Clin Pharmacol Ther 1991;50:233-8.
16. Otton SV, Inaba T, Kalow W. Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. Life Sci 1984;34:73-80.
17. Nielsen MD, Brøsen K, Gram LF. A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. Br J Clin Pharmacol 1990; 29:299-304.
18. Broly F, Vandamme N, Caron J, Libersa C, Lhermitte M. Single dose quinidine treatment inhibits mexiletine oxidation in extensive metabolisers of debrisoquine. Life Sci 1991;48:123-8.
19. Inaba T, Otton SV, Kalow W. Deficient metabolism of debrisoquine and sparteine. Clin Pharmacol Ther 1980;27:547-9.
20. Leeman T, Dayer P, Meyer UA. Single dose quinidine treatment inhibits metoprolol oxidation in extensive metabolisers. Eur J Clin Pharmacol 1986;29:739-41.
21. Zhang Y, Britto MR, Valderhaug KL, Wedlund PJ, Smith RA. Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther 1992;51:647-55.
22. Chen ZR, Somogyi AA, Bochner F. Dextromethorphan: pharmacogenetics and a pilot study to determine its disposition and antitussive effects in poor and extensive metabolisers. Eur J Clin Pharmacol 1990; 183:1573-4.
23. Vetticaden SJ, Cabana BE, Prasad VK, Purich ED, Jonkman JHJ, Zeeuw R, et al. Phenotypic differences in dextromethorphan metabolism. Pharm Res 1989;6:13-9.
24. Chen ZR, Somogyi AA, Bochner F. Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Ther Drug Monit 1990;12:97-104.
25. Rowland M, Tozer TN. Clinical Pharmacokinetics: concepts and applications. 2nd ed. Philadelphia: Lea & Febiger, 1989.
26. Kalant H, Roschlau WHE. Principles of medical pharmacology. 5th ed. Toronto: BC Decker, 1989:750.
27. 1 activity. Clin Pharmacol Ther 1989;45:34-40.
28. Bochner F, Somogyi AA, Chen ZR. Dextromethorphan metabolism in rat: interstrain differences and the fate of individually administered oxidative metabolites. Xenobiotica 1994;24:543-52.
29. Kamm JJ, Taddeo AB, van Loon EJ. Metabolism and excretion of tritiated dextromethorphan by the rat. J Pharmacol Exp Ther 1967;158:437-44.
30. Otton SV, Brinn R, Gram LF. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of the liver. Drug Metab Dispos 1988;16:15-7.
31. Otton SV, Inaba T, Kalow W. Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs. Life Sci 1983;32:795-800.
32. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P450. Mol Pharmacol 1986;30:287-95.
33. Brinn R, Brøsen K, Gram LF, Haghfelt T, Otton SV. Sparteine oxidation is practically abolished in quinidine treated patients. Br J Clin Pharmacol 1986;22:194-7.
34. Inaba T, Tyndale RE, Mahon WA. Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo. Br J Clin Pharmacol 1986;22:199-200.
35. Speirs CJ, Murray S, Boobis AR, Seddon CE, Davies DS. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolisers of debrisoquine. Br J Clin Pharmacol 1986;22:739-43.
36. Brøsen K, Gram LF, Haghfelt T, Bertilsson L. Extensive metabolisers of debrisoquine become poor metabolisers during quinidine treatment. Pharmacol Toxicol 1987;60:312-4.
37. Kobayashi S, Speirs CJ, Watson D, Murray S, Sesardic D, Boobis AR. Time course of inhibition by quinidine of debrisoquine 4-hydroxylase activity in man. Br J Clin Pharmacol 1988;25:673P-4P.
38. Funck-Brentano C, Turgeon J, Woosley RL, Roden DM. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. J Pharmacol Exp Ther 1989;249: 134-42.
39. Eichelbaum M, Reetz KP, Schmidt EK, Zekorn C. The genetic polymorphism of sparteine metabolism. Xenobiotica 1986;16:465-81.
40. Boobis AR, Murray S, Kahn GC, Robertz GM, Davies DS. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man. Mol Pharmacol 1983;23:474-81.
41. Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver chromosomes. J Pharmacol Exp Ther 1988;247:242-7.
42. Bickerman HA, German E, Cohen BM, Itkin SE. The cough response of healthy human subjects stimulated by citric acid aerosol; part II: evaluation of antitussive agents. Am J Med Sci 1957;234:191-205.
43. Calesnick B, Christensen JA. Latency of cough response as a measure of antitussive agents. Clin Pharmacol Ther 1966;8:374-80.
44. Karttunen P, Tukiainen H, Silvasti M, Kolonen S. Antitussive effect of dextromethorphan and dextromethorphan-salbutamol combination in healthy volunteers with artificially induced cough. Respiration 1987;52:49-53.
45. Grattan TJ, Marshall AE, Higgins KS, Morice AH. The effect of inhaled and oral dextromethorphan on citric acid induced cough in man. Br J Clin Pharmacol 1995;39:261-3.
46. Gravenstein JS, Devloo RA, Beecher HK. Effect of antitussive agents on experimental and pathological cough in man. J Appl Physiol 1954;7:119-39.
47. Empey DW, Laitinen LA, Young GA, Bye CE, Hughes DTD. Comparison of the antitussive effects of codeine phosphate 20 mg, dextromethorphan 30 mg, and noscapine 30 mg using citric acid-induced cough in normal subjects. Eur J Clin Pharmacol 1979;16:393-7.
48. Fuller RW, Haase G, Choudry NB. The effects of dextromethorphan cough syrup on capsaicin-induced cough in normal volunteers [abstract]. Am Rev Resp Dis 1989;A11:739.
49. Barros MJ, Zammattio SL, Rees PJ. Effect of changes in inspiratory flow rate on cough responses to inhaled capsaicin. Clin Sci 1991;81:539-42.
50. Rees PJT, Clark JH. Assessment of antitussive effects by citric acid threshold. Br J Dis Chest 1983; 77:94-7.
51. Pounsford JC, Birch MJ, Saunders KB. Effect of bronchodilators on the cough response to inhaled citric acid in normal and asthmatic subjects. Thorax 1985; 40:662-7.
52. Collier JG, Fuller RW. Capsaicin inhalation in man and the effects of sodium cromoglycate. Br J Pharmacol 1984;81:113-7.
53. Fuller RW, Choudry NB. Increased cough reflex associated with angiotensin converting enzyme inhibitor cough. Br Med J 1987;295:1025-6.
54. Fuller RW, Dixon CMS, Barnes PJ. Bronchoconstrictor response to inhaled capsaicin in humans. J Appl Physiol 1985;58:1080-4.
55. Fuller RW, Karlsson JA, Choudry NB, Pride NB. Effect of inhaled and systemic opiates on responses to inhaled capsaicin in humans. J Appl Physiol 1988;65: 1125-30.
56. Widdicombe JG. Receptors in the trachea and bronchi of the cat. J Physiol 1954;123:71-104.
57. Lowry RH, Wood AM, Higenbottam TW. Effects of pH and osmolarity on aerosol-induced cough in normal volunteers. Clin Sci 1988;74:373-6.
58. Adcock JJ. Peripheral opioid receptors and the cough reflex. Resp Med 1991;85 (suppl A):43-6.
59. Tatar M, Webber SE, Widdicombe JG. Lung C-fibre activation and defensive reflexes in anaesthetized cats. J Physiol 1988;402:411-20.
60. Idle JR, Mahgoub A, Lancaster R, Smith RL. Hypotensive response to debrisoquine and hydroxylation phenotype. Life Sci 1978;22:979-84.
61. Desmeules J, Gascon MP, Dayer P, Magistris M. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 1991;41:23-6.
62. Sindrup SH, Brøsen K, Bjerring P, Arendt-Nielsen L, Larsen U, Angelo HR, et al. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther 1990;48:686-93.
63. Braga PC, Fossati A, Vimercati MG, Caputo R, Guffanti EE. Dextrorphan and dextromethorphan: comparative antitussive effects on guinea pigs. Drugs Exp Clin Res 1994;20:199-203.